CytoMed Therapeutics (GDTC) announced that it has entered into a Memorandum of Understanding, MoU, with Universiti Malaya Medical Centre, UMMC, a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta T cells, CTM-GDT, for no-option cancer patients in Malaysia.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed completes acquisition of T cell technology of TC BioPharm
- CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India
- Cytomed Therapeutics secures investment for subsidiary LongevityBank
- CytoMed Therapeutics Secures Investment and Advances China Strategy
- CytoMed Therapeutics’ ANGELICA Trial: A New Frontier in Cancer Treatment